共 66 条
[1]
Culp MB(2020)Recent global patterns in prostate cancer incidence and mortality rates Eur Urol undefined undefined-undefined
[2]
Soerjomataram I(2015)Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Ann Oncol undefined undefined-undefined
[3]
Gillessen S(2019)Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer BJU Int undefined undefined-undefined
[4]
Omlin A(2016)177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy J Nucl Med undefined undefined-undefined
[5]
Yaxley JW(2017)German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients J Nucl Med undefined undefined-undefined
[6]
Raveenthiran S(2021)[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial Lancet undefined undefined-undefined
[7]
Baum RP(2021)Lutetium-177-PSMA-617 for metastatic castrationresistant prostate cancer N Engl J Med undefined undefined-undefined
[8]
Kulkarni HR(2022)EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA) Eur J Nucl Med Mol Imaging undefined undefined-undefined
[9]
Rahbar K(2009)From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med undefined undefined-undefined
[10]
Ahmadzadehfar H(2017)Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer J Nucl Med undefined undefined-undefined